ArticleCureus2025
Evaluating Pro- and Anti-inflammatory Biomarkers for Predicting Type 2 Diabetes Mellitus in the Geriatric Population and Correlation With Clinical and Biochemical Parameters.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Observational
- Circulating Beta-Defensin 2 Levels Correlate with Conventional Inflammatory Markers in Infection-Free Individuals with Overweight and Obesity: An Exploratory Study.Biomedicines · 2025Article
- Blood Cell Count-Based Inflammatory Markers Exhibit Superior Association with Diabetic Peripheral Neuropathy Compared to Protein-Based Markers.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Type 2 diabetes mellitus (T2DM) and aging are associated with inflammation. Our study investigates the diagnostic accuracy of pro- and anti-inflammatory biomarkers in predicting T2DM in the geriatric population and the relation of these biomarkers with clinical and biochemical parameters. Methods This case-control study included age-gender matched, 100 treatment-naïve T2DM cases, and 100 healthy controls. Clinical, biochemical, and anthropometric parameters were comprehensively profiled. The biomarkers were quantified by enzyme-linked immunosorbent assay (ELISA) methods. Results In the T2DM group, serum analyses revealed markedly elevated levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and cortisol, along with notably reduced concentrations of interleukin-10 (IL-10) and adiponectin compared to controls. Despite lower mean insulin-like growth factor-1 (IGF-1) levels in the T2DM group, the differences did not reach statistical significance. The risk of T2DM increased with elevated levels of CRP (odds ratio (OR): 2.69), TNF-α (OR: 1.20), IL-6 (OR: 1.83), and cortisol (OR: 1.01), while higher concentrations of adiponectin (OR: 0.81) and IL-10 (OR: 0.88) were associated with reduced risk (P < 0.05). CRP, TNF-α, IL-6, cortisol, adiponectin, and IL-10 all showed significant area under the curve (AUC) values (P < 0.05), confirming their diagnostic potential. Conversely, insulin-like growth factor-1 (IGF-1) did not reveal any significant diagnostic utility (P=0.327). The optimal cutoff values to diagnose T2DM in the geriatric population determined using the Youden index were as follows: CRP (>3.80 μg/ml), TNF-α (>22.90 pg/ml), IL-6 (>4.67 pg/ml), cortisol (>103.15 ng/ml), adiponectin (≤7.42 μg/ml), and IL-10 (≤5.19 pg/ml). Conclusion This study reveals that pro- and anti-inflammatory biomarkers can predict T2DM, have diagnostic potential and, serve as guidance for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.